TABLE 1.
General characteristics of GENOA subjects
| GENOA | European Americans | African Americans | Mexican Americans | F-Test |
|---|---|---|---|---|
| Subjects | 1,409 | 1,696 | 1,643 | |
| Families | 498 | 583 | 415 | |
| Diabetics | 161 | 354 | 1002 | |
| Hypertensives | 1,067 | 1,268 | 815 | |
| Age | 55.92 ± 10.89 | 57.94 ± 10.26 | 55.72 ± 12.08 | <0.0001 |
| Height (cm) | 168.73 ± 9.25 | 168.71 ± 8.81 | 162.94 ± 9.21 | <0.0001 |
| Weight (kg) | 86.67 ± 19.93 | 87.77 ± 18.69 | 81.88 ± 17.30 | <0.0001 |
| BMI (kg/m2) | 30.36 ± 6.30 | 30.90 ± 6.59 | 30.83 ± 6.08 | 0.042 |
| W/H | 0.913 ± 0.09 | 0.910 ± 0.07 | 0.974 ± 0.08 | <0.0001 |
| TC | 210.49 ± 38.79 | 205.10 ± 56.88 | 205.22 ± 46.36 | 0.0008 |
| LDL-C | 121.40 ± 33.90 | 120.70 ± 40.80 | 116.40 ± 35.50 | 0.0017 |
| HDL-C | 51.53 ± 16.35 | 55.52 ± 17.99 | 44.89 ± 12.64 | <0.0001 |
| TG | 193.59 ± 103.58 | 145.45 ± 90.87 | 234.18 ± 176.99 | <0.0001 |
| ApoE | 5.16 ± 1.65 | 5.31 ± 2.20 | 5.43 ± 2.22 | 0.0014 |
| ApoB | 106.65 ± 23.12 | 102.59 ± 25.95 | 108.54 ± 26.30 | <0.0001 |
| ApoA-I | 157.47 ± 31.36 | 158.83 ± 32.26 | 144.91 ± 25.67 | <0.0001 |
| Glucose | 100.11 ± 28.84 | 111.90 ± 49.09 | 152.82 ± 71.90 | <0.0001 |
| Lipid-lowering medication | 21.38% | 7.6% | 19.77% | |
| Anti-hypertensive medication | 68.88% | 66.8% | 49.84% | |
| Anti-diabetic medication | 8.28% | 21.98% | 62.66% |
GENOA, Genetic Epidemiology Network of Arteriopathy study; ApoE, apolipoprotein E; BMI, body mass index; W/H, waist-to-hip ratio; TG, triglycerides, HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TC, total cholesterol. Plasma levels of lipids, lipoproteins, apolipoproteins, and glucose are measured in mg/dl. Data are given as mean ± SD. Percentages of individuals taking medications were calculated for 991 African Americans, 1,196 Mexican Americans, and 1,038 European Americans.